Chemotherapy-induced painful neuropathy: Pain-like behaviours in rodent models and their response to commonly used analgesics

Current Opinion in Supportive and Palliative Care

Volumn 10, Issue 2, 2016, Pages 119-128

  Hopkins, Holly L ^a   Duggett, Natalie A ^a   Flatters, Sarah J L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

bortezomib; chemotherapy induced neuropathy; neurotoxicity; oxaliplatin; paclitaxel

Indexed keywords

4 AMINOBUTYRIC ACID; AMINE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; GABAPENTIN; NARCOTIC ANALGESIC AGENT; OXALIPLATIN; PLATINUM COMPLEX; PROTEASOME INHIBITOR; TAXOID;

ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; PAIN; PERIPHERAL NEUROPATHY; RODENT;

AMINES; ANALGESICS, OPIOID; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; CISPLATIN; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; ORGANOPLATINUM COMPOUNDS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASOME INHIBITORS; RODENTIA; TAXOIDS;

EID: 84966339992     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000204     Document Type: Review

References (118)

1. Dougherty PM, Cata JP, Cordella JV, et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004; 109: 132-142
2. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691
3. Argyriou AA, Koltzenburg M, Polychronopoulos P, et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008; 66: 218-228
4. Argyriou AA, Polychronopoulos P, Iconomou G, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 2007; 46: 1131-1137
5. Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 2009; 144: 245-252
6. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 2009; 10: 1146-1150
7. van Den Bent MJ, van Raaij-van Den Aarssen VJ, Verweij J, et al. Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 1997; 20: 750-752
8. Boyette-Davis JA, Cata JP, Zhang H, et al. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J Pain 2011; 12: 1017-1024
9. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-1967
10. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012; 82: 51-77
11. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014; 155: 2461-2470
12. Nogales E, Wolf SG, Khan IA, et al. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 1995; 375: 424-427
13. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007; 7: 730-742
14. Verweij J, Clavel M, Chevalier B. Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): not simply two of a kind. Ann Oncol 1994; 5: 495-505
15. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-5551
16. Roytta M, Horwitz SB, Raine CS. Taxol-induced neuropathy: short-term effects of local injection. J Neurocytol 1984; 13: 685-701
17. Roytta M, Raine CS. Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ. J Neurocytol 1985; 14: 157-175
18. Roytta M, Raine CS. Taxol-induced neuropathy: chronic effects of local injection. J Neurocytol 1986; 15: 483-496
19. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001; 94: 293-304
20. Flatters SJL, Bennett GJ. Ethosuximide reverses paclitaxel-and vincristineinduced painful peripheral neuropathy. Pain 2004; 109: 150-161
21. Dina OA, Chen X, Reichling D, Levine JD. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2001; 108: 507-515
22. Authier N, Gillet JP, Fialip J, et al. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res 2000; 887: 239-249
23. Cavaletti G, Cavalletti E, Montaguti P, et al. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997; 18: 137-145
24. Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29: 87-90
25. Gauchan P, Andoh T, Ikeda K, et al. Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. Biol Pharm Bull 2009; 32: 732-734
26. Gauchan P, Andoh T, Kato A, et al. Effects of the prostaglandin E1 analog limaprost on mechanical allodynia caused by chemotherapeutic agents in mice. J Pharmacol Sci 2009; 109: 469-472
27. Smith SB, Crager SE, Mogil JS. Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains. Life Sci 2004; 74: 2593-2604
28. Peng P, Xi Q, Xia S, et al. Pregabalin attenuates docetaxel-induced neuropathy in rats. J Huazhong Univ Sci Technolog Med Sci 2012; 32: 586-590
29. Roglio I, Bianchi R, Camozzi F, et al. Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Peripher Nerv Syst 2009; 14: 36-44
30. Cliffer KD, Siuciak JA, Carson SR, et al. Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 1998; 43: 46-55
31. Cavaletti G, Bogliun G, Marzorati L, et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 1995; 75: 1141-1150
32. Flatters SJL, Bennett GJ. Studies of peripheral sensory nerves in paclitaxelinduced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122: 245-257
33. Peters CM, Jimenez-Andrade JM, Jonas BM, et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 2007; 203: 42-54
34. Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-494
35. Authier N, Coudore F, Eschalier A, Fialip J. Pain related behaviour during vincristine-induced neuropathy in rats. Neuroreport 1999; 10: 965-968
36. Wang MS, Davis AA, Culver DG, Glass JD. WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann Neurol 2002; 52: 442-447
37. Macquet JP, Theophanides T. DNA-platinum interactions in vitro with transand cis-Pt(NH3)2Cl2. Bioinorg Chem 1975; 5: 59-66
38. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4-12
39. Joseph EK, Levine JD. Comparison of oxaliplatin-and cisplatin-induced painful peripheral neuropathy in the rat. J Pain 2009; 10: 534-541
40. Nassini R, Gees M, Harrison S, et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 2011; 152: 1621-1631
41. Gauchan P, Andoh T, Kato A, Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett 2009; 458: 93-95
42. Andoh T, Kitamura R, Kuraishi Y. Milnacipran inhibits oxaliplatin-induced mechanical allodynia through spinal action in mice. Biol Pharm Bull 2015; 38: 151-154
43. Zhao M, Isami K, Nakamura S, et al. Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain 2012; 8: 55
44. Zhao M, Nakamura S, Miyake T, et al. Pharmacological characterization of standard analgesics on oxaliplatin-induced acute cold hypersensitivity in mice. J Pharmacol Sci 2014; 124: 514-517
45. Descoeur J, Pereira V, Pizzoccaro A, et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med 2011; 3: 266-278
46. Kim W, Kim MJ, Go D, et al. Combined effects of bee venom acupuncture and morphine on oxaliplatin-induced neuropathic pain in mice. Toxins (Basel) 2016; 8: pii: E33. doi: 10.3390/toxins8020033
47. Ohsawa M, Otake S, Murakami T, et al. Gabapentin prevents oxaliplatininduced mechanical hyperalgesia in mice. J Pharmacol Sci 2014; 125: 292-299
48. Salat K, Cios A, Wyska E, et al. Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. Pharmacol Biochem Behav 2014; 122: 173-181
49. Ling B, Coudore-Civiale MA, Balayssac D, et al. Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology 2007; 234: 176-184
50. Balayssac D, Ling B, Ferrier J, et al. Assessment of thermal sensitivity in rats using the thermal place preference test: description and application in the study of oxaliplatin-induced acute thermal hypersensitivity and inflammatory pain models. Behav Pharmacol 2014; 25: 99-111
51. Aoki M, Mori A, Nakahara T, et al. Salmon calcitonin reduces oxaliplatininduced cold and mechanical allodynia in rats. Biol Pharm Bull 2013; 36: 326-329
52. Ling B, Coudore F, Decalonne L, et al. Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology 2008; 55: 724-728
53. Boyette-Davis J, Dougherty PM. Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp Neurol 2011; 229: 353-357
54. Azevedo MI, Pereira AF, Nogueira RB, et al. The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy. Mol Pain 2013; 9: 53
55. Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012; 203: 194-206
56. Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel-and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011; 232: 154-161
57. Ruyang T, Yang Z, Wei F. Gabapentin prevents oxaliplatin-induced central sensitization in the dorsal horn neurons in rats. Iran J Basic Med Sci 2015; 18: 493-498
58. Kanbara T, Nakamura A, Shibasaki M, et al. Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model. Neurosci Lett 2014; 580: 119-124
59. Mori T, Kanbara T, Harumiya M, et al. Establishment of opioid-induced rewarding effects under oxaliplatin-and paclitaxel-induced neuropathy in rats. J Pharmacol Sci 2014; 126: 47-55
60. Fardell JE, Vardy J, Monds LA, Johnston IN. The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy. Behav Brain Res 2015; 291: 80-88
61. Ghirardi O, Lo Giudice P, Pisano C, et al. Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 2005; 25: 2681-2687
62. AlMoundhri MS, Al-Salam S, AlMahrouqee A, et al. The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical and histopathological studies. J Med Toxicol 2013; 9: 25-33
63. Joseph EK, Chen X, Bogen O, Levine JD. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 2008; 9: 463-472
64. Renn CL, Carozzi VA, Rhee P, et al. Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain 2011; 7: 29
65. Ta LE, Low PA, Windebank AJ. Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 2009; 5: 9
66. Ling B, Authier N, Balayssac D, et al. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 2007; 128: 225-234
67. Kanbara T, Nakamura A, Takasu K, et al. The contribution of Gi/o protein to opioid antinociception in an oxaliplatin-induced neuropathy rat model. J Pharmacol Sci 2014; 126: 264-273
68. Sada H, Egashira N, Ushio S, et al. Repeated administration of amitriptyline reduces oxaliplatin-induced mechanical allodynia in rats. J Pharmacol Sci 2012; 118: 547-551
69. Egashira N, Hirakawa S, Kawashiri T, et al. Mexiletine reverses oxaliplatininduced neuropathic pain in rats. J Pharmacol Sci 2010; 112: 473-476
70. Liu X, Zhang G, Dong L, et al. Repeated administration of mirtazapine attenuates oxaliplatin-induced mechanical allodynia and spinal NR2B upregulation in rats. Neurochem Res 2013; 38: 1973-1979
71. Toyama S, Shimoyama N, Ishida Y, et al. Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies. Anesthesiology 2014; 120: 459-473
72. Cata JP, Weng HR, Dougherty PM. Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res 2008; 1230: 91-98
73. Boyle FM, Beatson C, Monk R, et al. The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol 2001; 48: 429-434
74. Guindon J, Lai Y, Takacs SM, et al. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 2013; 67: 94-109
75. Vera G, Chiarlone A, Cabezos PA, et al. WIN 55 212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007; 81: 468-479
76. Park HJ, Stokes JA, Pirie E, et al. Persistent hyperalgesia in the cisplatintreated mouse as defined by threshold measures, the conditioned place preference paradigm and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac and etanercept. Anesth Analg 2013; 116: 224-231
77. Woller SA, Corr M, Yaksh TL. Differences in cisplatin-induced mechanical allodynia in male and female mice. Eur J Pain 2015; 19: 1476-1485
78. Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 1999; 41: 107-116
79. Tredici G, Tredici S, Fabbrica D, et al. Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. J Neurooncol 1998; 36: 31-40
80. Marcus DJ, Zee M, Hughes A, et al. Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase. Mol Pain 2015; 11: 34
81. Authier N, Gillet JP, Fialip J, et al. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003; 182: 12-20
82. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9: 6316-6325
83. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001; 28: 613-619
84. Engelhardt M, Kleber M, Udi J, et al. Consensus statement from European experts on the diagnosis, management and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010; 51: 1424-1443
85. Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003; 29 (Suppl 1): 21-31
86. Huang Z, Wu Y, Zhou X, et al. Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol 2014; 10: 1795-1807
87. Kitamura R, Andoh T, Mizoguchi S, et al. Gabapentin inhibits bortezomibinduced mechanical allodynia through supraspinal action in mice. J Pharmacol Sci 2014; 124: 502-510
88. Boehmerle W, Huehnchen P, Peruzzaro S, et al. Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Sci Rep 2014; 4: 6370
89. Yamamoto S, Kawashiri T, Higuchi H, et al. Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats. J Pharmacol Sci 2015; 129: 43-50
90. Robinson CR, Zhang H, Dougherty PM. Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy. Brain Res 2014; 1574: 6-13
91. Zheng H, Xiao WH, Bennett GJ. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol 2012; 238: 225-234
92. Meregalli C, Canta A, Carozzi VA, et al. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010; 14: 343-350
93. Quartu M, Carozzi VA, Dorsey SG, et al. Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP and substance P in the rat DRG, spinal cord and sciatic nerve. Biomed Res Int 2014; 2014: 180428
94. Carozzi VA, Renn CL, Bardini M, et al. Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse. PLoS One 2013; 8: e72995
95. Bruna J, Udina E, Ale A, et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 2010; 223: 599-608
96. Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007; 8: 296-306
97. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, noninferiority study. Lancet Oncol 2011; 12: 431-440
98. Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 2012; 51: 823-829
99. Hoy SM. Subcutaneous bortezomib: in multiple myeloma. Drugs 2013; 73: 45-54
100. Xu Y, Deng S, An G, et al. Subcutaneous administration of bortezomib significantly decreased and delayed the development of peripheral neuropathy in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 2015; 15: e163
101. Barbee MS, Harvey RD, Lonial S, et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother 2013; 47: 1136-1142
102. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309: 1359-1367
103. Ito S, Tajima K, Nogawa M, et al. Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. J Pharmacol Exp Ther 2012; 342: 53-60
104. Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008; 35: 31-39
105. Gewandter JS, Mohile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer 2014; 22: 1807-1814
106. Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011; 19: 833-841
107. Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med 2008; 9: 505-517
108. Han FY, Wyse BD, Smith MT. Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic pain. Behav Pharmacol 2014; 25: 732-740
109. Durand JP, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 2005; 16: 587-591
110. Katsuyama S, Sato K, Yagi T, et al. Effects of repeated milnacipran and fluvoxamine treatment on mechanical allodynia in a mouse paclitaxel-induced neuropathic pain model. Biomed Res 2013; 34: 105-111
111. Pascual D, Goicoechea C, Burgos E, Martin MI. Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats. Pharmacol Biochem Behav 2010; 95: 331-337
112. Xu F, Xu S, Wang L, et al. Antinociceptive efficacy of verticinone in murine models of inflammatory pain and paclitaxel induced neuropathic pain. Biol Pharm Bull 2011; 34: 1377-1382
113. Balayssac D, Cayre A, Ling B, et al. Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy. Neurosci Lett 2009; 465: 108-112
114. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007; 110: 2110-2118
115. Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 2007; 144: 714-720
116. Huehnchen P, Boehmerle W, Endres M. Assessment of paclitaxel induced sensory polyneuropathy with 'catwalk' automated gait analysis in mice. PLoS One 2013; 8: e76772
117. Vondracek P, Oslejskova H, Kepak T, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol 2009; 13: 332-336
118. Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res 2010; 30: 2927-2933